ES2178038T3 - Nuevos derivados de ciclosporina, su preparacion y las composiciones farmaceuticas que los contienen. - Google Patents

Nuevos derivados de ciclosporina, su preparacion y las composiciones farmaceuticas que los contienen.

Info

Publication number
ES2178038T3
ES2178038T3 ES97952999T ES97952999T ES2178038T3 ES 2178038 T3 ES2178038 T3 ES 2178038T3 ES 97952999 T ES97952999 T ES 97952999T ES 97952999 T ES97952999 T ES 97952999T ES 2178038 T3 ES2178038 T3 ES 2178038T3
Authority
ES
Spain
Prior art keywords
rent
bencilo
links
alkyl
general formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97952999T
Other languages
English (en)
Inventor
Jean-Claude Barriere
Georges Bashiardes
Jean-Christophe Carry
Michel Evers
Bruno Filoche
Serge Mignani
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Aventis Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma SA filed Critical Aventis Pharma SA
Application granted granted Critical
Publication of ES2178038T3 publication Critical patent/ES2178038T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C07K7/645—Cyclosporins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

LA INVENCION SE REFIERE A DERIVADOS DE CICLOSPORINA DE FORMULA GENERAL (I) EN LA QUE ALK ES ALQUILENO DE 2 A 6 C EN CADENA RECTA O RAMIFICADA O CICLOALQUILENO QUE CONTIENE DE 3 A 6 C Y R ES: BIEN OH, COOH O ALQUILOXICARBONILO, O BIEN NR 1 R 2 PARA EL CUAL R 1 , R 2 IDENTICOS O DIFERENTES SON H, O ALQUILO, ALCENILO (2 A 4 C), CICLOALQUILO (3 A 6 C), FENILO OPCIONALMENTE SUSTITUIDO (POR HALOGENO, ALQUILOXILO, ALQUILOXICARBONILO, AMINO, ALQUILAMINO O DIALQUILAMINO) O SON RADICALES BENCILO O HETEROCICLILO SATURADO O INSATURADO QUE CONTIENE 5 O 6 ESLABONES Y 1 A 3 HETEROATOMOS O PARA EL CUAL R SUB,1 Y R 2 FORMAN CON EL ATOMO DE NITROGENO AL QUE ESTAN U NIDOS UN HETEROCICLO QUE CONTIENE DE 4 A 6 ESLABONES QUE PUEDEN CONTENER OTRO HETEROATOMO ELEGIDO ENTRE N, O O S Y OPCIONALMENTE SUSTITUIDO POR ALQUILO, FENILO O BENCILO, BIEN UN RADICAL DE FORMULA GENERAL (I'') PARA EL CUAL R 1 Y R 2 ESTAN DEFINIDO COMO ANTERIORMENTE, R 3 ES H O ALQUILO Y N ES UN NUMERO ENTERO DE 2 A 4, SIENDO LAS PARTES O RADICALES DE ALQUILO DEFINIDOS ANTERIORMENTE RECTOS O RAMIFICADOS Y CONTENIENDO ENTRE 1 Y 4 ATOMOS DE CARBONO, ASI COMO SUS SALES FARMACEUTICAMENTE ACEPTABLES CUANDO EXISTEN. ESTOS NUEVOS PRODUCTOS SON PARTICULARMENTE UTILES PARA EL TRATAMIENTO Y/O LA PROFILAXIS DE LAS INFECCIONES CON RETROVIRUS.
ES97952999T 1996-12-24 1997-12-23 Nuevos derivados de ciclosporina, su preparacion y las composiciones farmaceuticas que los contienen. Expired - Lifetime ES2178038T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9615955A FR2757521B1 (fr) 1996-12-24 1996-12-24 Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent

Publications (1)

Publication Number Publication Date
ES2178038T3 true ES2178038T3 (es) 2002-12-16

Family

ID=9499088

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97952999T Expired - Lifetime ES2178038T3 (es) 1996-12-24 1997-12-23 Nuevos derivados de ciclosporina, su preparacion y las composiciones farmaceuticas que los contienen.

Country Status (14)

Country Link
US (1) US5994299A (es)
EP (1) EP0951474B1 (es)
JP (1) JP4146518B2 (es)
AT (1) ATE218582T1 (es)
AU (1) AU5669398A (es)
DE (1) DE69713152D1 (es)
DK (1) DK0951474T3 (es)
ES (1) ES2178038T3 (es)
FR (1) FR2757521B1 (es)
MA (1) MA26458A1 (es)
PT (1) PT951474E (es)
TN (1) TNSN97212A1 (es)
WO (1) WO1998028330A1 (es)
ZA (1) ZA9711607B (es)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030220234A1 (en) 1998-11-02 2003-11-27 Selvaraj Naicker Deuterated cyclosporine analogs and their use as immunodulating agents
ATE254630T1 (de) * 1998-06-12 2003-12-15 Chem Ag C Cyclosporine
FR2780061B1 (fr) * 1998-06-22 2001-09-07 Rhone Poulenc Rorer Sa Nouveau procede de preparation de derives de cyclosporine
PT1091975E (pt) 1998-07-01 2006-05-31 Debiopharm Sa Nova ciclosporina com um perfil de actividade melhorado
US6254860B1 (en) * 1999-04-13 2001-07-03 Allergan Sales, Inc. Ocular treatment using cyclosporin-A derivatives
WO2001013957A2 (en) 1999-08-24 2001-03-01 Cellgate, Inc. Enhancing drug delivery across and into epithelial tissues using oligo arginine moieties
KR100465012B1 (ko) * 2001-05-11 2005-01-13 주식회사 엘지생활건강 모발 성장 효과를 갖는 사이클로스포린 3 위치 유도체를유효성분으로 하는 모발 성장 촉진제
HRP20070058B1 (hr) 2001-10-19 2014-05-23 Isotechnika Inc. Sinteza ciklosporinskih analoga
EP1435910B9 (en) * 2001-10-19 2010-02-03 Isotechnika Inc. Novel cyclosporin analog microemulsion preconcentrates
US6987090B2 (en) * 2002-05-09 2006-01-17 Lg Household & Health Care Ltd. Use of 3-position cyclosporin derivatives for hair growth
KR20040039622A (ko) * 2002-11-04 2004-05-12 주식회사 엘지생활건강 모발 성장 효과를 갖는 사이클로스포린 3 위치 유도체를유효성분으로 하는 모발 성장 촉진제
CA2518265A1 (en) 2003-03-17 2004-09-30 Albany Molecular Research, Inc. Novel cyclosporins
GB0320638D0 (en) * 2003-09-03 2003-10-01 Novartis Ag Organic compounds
US7780973B2 (en) * 2003-12-15 2010-08-24 Ethicon Endo-Surgery, Inc. Method and device for minimally invasive implantation of biomaterial
US20050142161A1 (en) * 2003-12-30 2005-06-30 Freeman Lynetta J. Collagen matrix for soft tissue augmentation
BRPI0513370A (pt) * 2004-07-14 2008-05-06 Novartis Ag uso de uma combinação de ciclosporina e interferonas peguilados para tratamento de hepatite c (hcv)
KR100597309B1 (ko) 2004-09-17 2006-07-05 주식회사 핸슨바이오텍 세베키아 베니하나를 이용한 [감마 히드록실메틸루신4] 사이클로스포린 a의 제조방법
JP2008514702A (ja) 2004-09-29 2008-05-08 エーエムアール テクノロジー インコーポレイテッド 新規シクロスポリン類似体およびそれらの薬学的使用
US7378391B2 (en) 2004-09-29 2008-05-27 Amr Technology, Inc. Cyclosporin alkyne analogues and their pharmaceutical uses
US7196161B2 (en) * 2004-10-01 2007-03-27 Scynexis Inc. 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis C infection
PT1802650E (pt) * 2004-10-01 2011-12-30 Scynexis Inc Derivados da ciclosporina 3-éter e 3-tioéter substituída para o tratamento e prevenção da infecção de hepatite c
WO2006041631A2 (en) 2004-10-06 2006-04-20 Amr Technology, Inc. Novel cyclosporin alkynes and their utility as pharmaceutical agents
US7691812B2 (en) * 2004-11-04 2010-04-06 Trustees Of The University Of Pennsylvania Methods for inhibiting growth of prolactin-responsive cancer cells with cyclosporine A or other cyclophilin inhibitors
NZ555142A (en) * 2004-12-23 2010-03-26 Novartis Ag Compounds for flaviviridae treatment
WO2006071619A1 (en) * 2004-12-23 2006-07-06 Novartis Ag Compositions for hcv treatment
WO2007041632A2 (en) * 2005-09-30 2007-04-12 Scynexis, Inc. Methods and pharmaceutical compositions for the treatment and prevention of hepatitis c infection
CN101316606B (zh) * 2005-09-30 2015-05-27 西尼克斯公司 治疗和预防丙型肝炎感染的方法和药物组合物
WO2007041631A1 (en) 2005-09-30 2007-04-12 Scynexis, Inc. ARYIiALKYL AND HETEROARYLALKYL DERIVATIVES OF CYCLOSPORINE A FOR THE TREATMENT AND PREVENTION OF VIRAL INFECTION
US7696165B2 (en) 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne analogues for preventing or treating viral-induced disorders
US7696166B2 (en) 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders
CA2652662C (en) 2006-05-19 2015-11-03 Scynexis, Inc. Methods for the treatment and prevention of ocular disorders
KR101089112B1 (ko) * 2006-06-02 2011-12-06 피씨 제스띠옹 에스.아.에스. 활성 전자 관리
KR20090083902A (ko) * 2006-10-12 2009-08-04 노파르티스 아게 개질된 사이클로스포린의 용도
WO2008069917A2 (en) 2006-11-20 2008-06-12 Scynexis, Inc. Novel cyclic peptides
WO2008127613A1 (en) * 2007-04-11 2008-10-23 Scynexis, Inc. New pharmaceutical compositions
US8394763B2 (en) 2007-09-26 2013-03-12 Oregon Health & Science University Cyclic undecapeptides and derivatives as multiple sclerosis therapies
US20090306033A1 (en) * 2008-06-06 2009-12-10 Keqiang Li Novel cyclic peptides
JP5820722B2 (ja) * 2008-06-06 2015-11-24 スシネキス インク シクロスポリン類似体及びｈｃｖ感染の治療におけるその使用
US8716238B2 (en) * 2008-07-10 2014-05-06 Allergan, Inc. Cyclosporin derivatives for treating ocular and dermal diseases and conditions
DE102008060549A1 (de) 2008-12-04 2010-06-10 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Wirkstoff-Peptid-Konstrukt zur extrazellulären Anreicherung
US8536114B2 (en) 2008-12-31 2013-09-17 Scynexis, Inc. Macrocycles
KR20110116136A (ko) * 2009-01-07 2011-10-25 싸이넥시스, 인크. Ｈｃｖ 및 ｈｉｖ 감염의 치료에 사용하기 위한 사이클로스포린 유도체
JP2012528163A (ja) 2009-05-27 2012-11-12 アラーガン、インコーポレイテッド 炎症性疾患および状態を処置するためのシクロスポリン誘導体
CA2785978A1 (en) 2009-12-30 2011-07-07 Scynexis, Inc. Cyclosporine analogues
US9217015B2 (en) 2010-07-16 2015-12-22 S&T Global Inc. Cyclosporin derivatives for the treatment and prevention of a viral infection
CN103153330B (zh) 2010-08-12 2017-08-18 美国科技环球有限公司 新的环孢霉素衍生物在病毒感染的治疗和预防中的应用
AU2011316690C1 (en) 2010-10-12 2017-01-19 Allergan, Inc. Cyclosporin analogs
EP2627663B1 (en) * 2010-10-12 2018-02-21 Allergan, Inc. Cyclosporin analogs
US9890198B2 (en) 2010-12-03 2018-02-13 S&T Global Inc. Cyclosporin derivatives and uses thereof
AU2011342284C1 (en) 2010-12-15 2017-07-13 Contravir Pharmaceuticals, Inc. Cyclosporine analogue molecules modified at amino acid 1 and 3
EP2705856A1 (en) 2012-09-07 2014-03-12 Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. Compounds for the treatment of neurodegenerative disorders
WO2020037530A1 (en) 2018-08-22 2020-02-27 Waterstone Pharmaceuticals (Wuhan) Co., Ltd. Crystalline form of compound and uses thereof in medicine
ES2987605T3 (es) * 2018-12-14 2024-11-15 Waterstone Pharmaceuticals Wuhan Co Ltd Maleato de SCY-635 y usos del mismo en medicina
WO2020118715A1 (en) * 2018-12-14 2020-06-18 Waterstone Pharmaceuticals (Wuhan) Co., Ltd. Salts of scy-635 and uses thereof in medicine
ES3064540T3 (en) * 2021-12-09 2026-04-27 Waterstone Pharmaceuticals Wuhan Co Ltd Ws635 for promoting wound healing

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0194972B1 (en) * 1985-03-11 1992-07-29 Sandoz Ag Novel cyclosporins
US4814323A (en) * 1986-03-25 1989-03-21 Andrieu J M Process for the treatment and the prevention of AIDS and other disorders induced by the LAV/HTLV III virus
FI111730B (fi) * 1990-11-02 2003-09-15 Novartis Ag Menetelmä ei-immunosuppressiivisen syklosporiinin valmistamiseksi
CN1141317C (zh) * 1995-07-17 2004-03-10 碳化学公司 有抗人体免疫缺损病毒作用的环孢菌素衍生物

Also Published As

Publication number Publication date
EP0951474A1 (fr) 1999-10-27
PT951474E (pt) 2002-11-29
DE69713152D1 (de) 2002-07-11
ZA9711607B (en) 1998-06-24
MA26458A1 (fr) 2004-12-20
FR2757521B1 (fr) 1999-01-29
US5994299A (en) 1999-11-30
DK0951474T3 (da) 2002-09-16
JP2001507347A (ja) 2001-06-05
AU5669398A (en) 1998-07-17
EP0951474B1 (fr) 2002-06-05
WO1998028330A1 (fr) 1998-07-02
JP4146518B2 (ja) 2008-09-10
ATE218582T1 (de) 2002-06-15
TNSN97212A1 (fr) 2005-03-15
FR2757521A1 (fr) 1998-06-26

Similar Documents

Publication Publication Date Title
GT199800180A (es) Derivados de la tienopirimidina y de la tienopiridina utiles como agentes anticancerigenos.
PA8472301A1 (es) Derivados de isotiazol utiles como agentes anticancerosos
ES2084944T3 (es) Amidas terapeuticas.
ES2076935T3 (es) Compuesto de pirazolopiridina y procedimientos para su preparacion.
DOP2001000170A (es) Derivados de tiofeno utiles como agentes anticancesoros
CU23132A3 (es) Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos
ES2070126T3 (es) Derivados de piridazinamina.
PA8547901A1 (es) Derivados de 4-piperacinilindol con afinidad receptora de 5-ht6
AR018033A1 (es) Analogos 13-oxa prostaglandinas, composicion farmaceutica que los contiene y su uso para la manufactura de un medicamento
PE108898A1 (es) Derivados 6,5-heterobiciclicos sustituidos
CY1106674T1 (el) Αζαδικυκλικοι ετεροκυκλοι σαν ρυθμιστες υποδοχεα κανναβινοειδους
UY28692A1 (es) Nuevos derivados de quinolina
ES2179996T3 (es) Cefalosporinas de vinil-pirrolidinona con sustituyentes basicos.
AR003453A1 (es) Inhibidores de agregado de plaquetas, su uso en la fabricacion de medicamentos, composicion farmaceutica que los contiene y procedimiento para la preparacion de dichos inhibidores
PA8556801A1 (es) Compuestos de imidazopiridin como moduladores de receptor 5-ht 4
SV2003000697A (es) Agonistas del receptor beta3-adrenergico y usos de los mismos ref. pc11008/700016/bb
PA8546601A1 (es) Nuevos derivados de indol con afinidad por el receptor 5-ht6
GT200100137A (es) Pro-drogas de derivados de 4-fenil-piridina.
CR7069A (es) Derivados de pirazol para el tratamiento de vih
PA8536001A1 (es) Derivados de quinazolona como antagonistas de receptores adrenérgicos alfa-1a/b
ES2194844T3 (es) Antagonistas del receptor de aminoacidos excitadores.
CO4810375A1 (es) Derivados de 9-amino-3-ceto eritromicina
PA8568101A1 (es) Indolil-urea derivados de tienopiridinas utiles como agentes antiangiogenicos, y procedimientos para su uso
PA8529501A1 (es) Nuevos tiadiazoles y oxadiazoles y su uso como inhibidores de fosfodiesterasa -7."
ID23954A (id) Tetrahidrogama-karbolin